Equilibrium Constants for (R)-[(S)-1-(4-Bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic Acid (NVP-AAM077) Acting at Recombinant NR1/NR2A and NR1/NR2B N-Methyl-d-aspartate Receptors: Implications for Studies of Synaptic Transmission
- 1 September 2006
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 70 (3) , 1022-1032
- https://doi.org/10.1124/mol.106.024042
Abstract
We have quantified the effects of the N-methyl-d-aspartate (NMDA) receptor antagonist (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) at rat recombinant N-methyl-d-aspartate receptor (NR)1/NR2A and NR1/NR2B NMDA receptors expressed in Xenopus laevis oocytes. We observed no difference in the steady-state levels of inhibition produced by NVP-AAM077 when it was either preapplied or coapplied with glutamate. The IC50 values for NVP-AAM077 acting at NR1/NR2A NMDA receptors were, as expected, dependent on the glutamate concentration used to evoke responses, being 31 ± 2 nM (with glutamate at its EC50 concentration) and 214 ± 10 nM (at 10 times the EC50 concentration). Schild analysis confirmed that the antagonism produced by NVP-AAM077 at NR1/NR2A NMDA receptors was competitive and gave an estimate of its equilibrium constant (KB) of 15 ± 2 nM. Furthermore, Schild analysis of an NMDA receptor carrying a threonine-to-alanine point mutation in the NR2A ligand binding site indicated that NVP-AAM077 still acted in a competitive manner but with its KB increased by around 15-fold. At NR1/NR2B NMDA receptors, NVP-AAM077 displayed reduced potency. An IC50 value of 215 ± 13 nM was obtained in the presence of the EC50 concentration of glutamate (1.5 μM), whereas a value of 2.2 ± 0.14 μM was obtained with higher (15 μM) glutamate concentrations. Schild analysis gave a KB for NVP-AAM077 at NR2B-containing receptors of 78 ± 3 nM. Finally, using a kinetic scheme to model “synaptic-like” activation of NMDA receptors, we show that the difference in the equilibrium constants for NVP-AAM077 is not sufficient to discriminate between NR2A-containing or NR2B-containing NMDA receptors.Keywords
This publication has 36 references indexed in Scilit:
- The Different Effects on Recognition Memory of Perirhinal Kainate and NMDA Glutamate Receptor Antagonism: Implications for Underlying Plasticity MechanismsJournal of Neuroscience, 2006
- Lack of NMDA Receptor Subtype Selectivity for Hippocampal Long-Term PotentiationJournal of Neuroscience, 2005
- Structural Features of the Glutamate Binding Site in Recombinant NR1/NR2A N-Methyl-D-aspartate Receptors Determined by Site-Directed Mutagenesis and Molecular ModelingMolecular Pharmacology, 2005
- Activation of NR1/NR2B NMDA receptorsNature Neuroscience, 2003
- 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor compositionBioorganic & Medicinal Chemistry Letters, 2002
- Single‐channel analysis of an NMDA receptor possessing a mutation in the region of the glutamate binding siteThe Journal of Physiology, 2000
- Identification of Amino Acid Residues of the NR2A Subunit That Control Glutamate Potency in Recombinant NR1/NR2A NMDA ReceptorsJournal of Neuroscience, 1998
- Structure‐activity analysis of binding kinetics for NMDA receptor competitive antagonists: the influence of conformational restrictionBritish Journal of Pharmacology, 1991
- Concentration-jump experiments with NMDA antagonists in mouse cultured hippocampal neuronsJournal of Neurophysiology, 1990
- SOME QUANTITATIVE USES OF DRUG ANTAGONISTSBritish Journal of Pharmacology and Chemotherapy, 1959